china
hepat
b
surfac
antigen
hbsag
seroposit
rate
gener
popul
year
age
global
million
individu
hepat
b
viru
hbv
infect
million
chronic
hepat
b
common
risk
factor
liver
cirrhosi
hepatocellular
carcinoma
hcc
mortal
hbvinduc
acuteonchron
liver
failur
aclf
may
exceed
hbv
infect
easi
cure
mechan
viru
unclear
particularli
regard
protein
express
regul
function
pathogen
process
proteom
analysi
power
technolog
use
myriad
studi
includ
focus
liver
diseas
isobar
tag
rel
absolut
quantit
itraq
quantit
method
common
tool
proteom
suggest
sensit
sensit
differenti
gel
electrophoresi
dige
techniqu
specif
itraq
method
use
studi
varieti
diseas
shown
effect
accur
purpos
studi
analyz
serum
protein
level
use
itraq
normal
control
well
patient
chronic
hepat
b
chb
hbvinduc
aclf
verifi
result
use
western
blot
ultim
aim
identifi
differ
serum
protein
level
close
associ
progress
hepat
b
hbvinduc
aclf
result
studi
may
provid
crucial
inform
regard
viral
mechan
pathogen
process
serum
sampl
healthi
individu
patient
chb
hbvinduc
aclf
obtain
depart
infecti
diseas
depart
tradit
chines
medicin
third
affili
hospit
sun
yatsen
univers
guangzhou
china
tabl
ii
hbvinduc
aclf
diagnos
use
previous
describ
criteria
exclus
criteria
includ
pregnant
lactat
femal
patient
treat
antivir
immunomodulatori
therapi
within
previou
six
month
presenc
factor
caus
activ
liver
diseas
eg
autoimmun
druginduc
liver
alcohol
liver
inherit
metabol
liver
diseas
concomit
human
immunodefici
viru
hiv
infect
congenit
immun
defici
diseas
liver
cancer
malign
sever
diabet
autoimmun
diseas
import
organ
dysfunct
eg
kidney
dysfunct
concomit
infect
eg
fever
leukocytosi
neutrophilia
manifest
abdomin
biliari
tract
lung
infect
seriou
comorbid
eg
hepat
encephalopathi
gastrointestin
bleed
studi
protocol
conform
ethic
guidelin
declar
helsinki
approv
appropri
institut
review
committe
third
affili
hospit
sun
yatsen
univers
guangzhou
china
bureau
health
guangdong
china
inform
patient
consent
obtain
prior
particip
studi
plasma
fraction
proteinmin
protein
enrich
smallcapac
kit
cat
proteinmin
biorad
laboratori
hercul
ca
usa
accord
manufactur
instruct
protein
solut
reduc
h
mm
dithiothreitol
dtt
cysteineblock
mm
iodoacetamid
iaa
room
temperatur
min
sampl
precipit
fourtim
volum
cold
aceton
total
protein
concentr
determin
use
bradford
assay
protein
solut
mgml
triethyl
ammonium
bicarbon
teab
contain
sodium
dodecyl
sulfat
ph
digest
h
tosylphenylalanyl
chloromethyl
keton
tpck
treat
trypsin
peptid
solut
label
h
room
temperatur
use
itraq
reagent
reconstitut
liter
ethanol
accord
itraq
reagent
multiplex
kit
instruct
appli
biosystem
foster
citi
ca
usa
reaction
termin
ad
milliq
water
sampl
label
masstag
itraq
reagent
scx
perform
remov
excess
itraq
reagent
interf
substanc
mass
analysi
label
peptid
dri
vacuum
centrifug
resuspend
ml
buffer
prior
load
phenomenex
luna
scx
column
mm
length
intern
diamet
phenomenex
inc
torranc
ca
usa
agil
hplc
unit
agil
technolog
santa
clara
ca
usa
buffer
consist
mm
acetonitril
ph
buffer
b
consist
mm
acetonitril
kcl
ph
min
gradient
compris
buffer
min
buffer
b
min
buffer
b
min
buffer
b
min
buffer
b
min
buffer
min
thirteen
fraction
collect
use
foxi
jr
fraction
collector
dionex
corp
sunnyval
ca
usa
fraction
pool
accord
chromatogram
profil
base
peak
intens
fraction
dri
vacuum
concentr
store
prior
analysi
use
mass
spectrometri
peptid
scx
fraction
dissolv
formic
acid
dilut
trifluoroacet
acid
tfa
peptid
load
onto
microtofq
iinano
lc
system
bruker
dalton
inc
billerica
usa
mass
spectra
acquir
mz
rang
everi
second
min
data
process
use
biotool
softwar
bruker
dalton
inc
file
subsequ
submit
inhous
mascot
server
matrix
scienc
ltd
london
uk
databas
screen
data
screen
human
sequenc
databas
nation
center
biotechnolog
inform
nonredund
ncbinr
search
perform
use
trypsin
specif
enzym
maximum
one
miss
cleavag
permit
oxid
itraq
plex
k
itraq
plex
nterm
select
variabl
modif
data
obtain
microtofq
search
peptid
mass
toler
ppm
fragment
mass
toler
da
protein
ratio
normal
use
overal
median
ratio
peptid
sampl
separ
ratio
everi
individu
experi
ratio
given
protein
calcul
take
averag
peptid
ratio
identifi
protein
final
list
protein
ratio
averag
protein
ratio
three
experi
consist
protein
discov
three
experi
function
definit
variabl
protein
content
search
use
follow
two
websit
http
wwwuniprotorg
http
wwwncbinlmnihgov
five
protein
creactiv
protein
crp
precursor
hemoglobin
chain
variant
hb
swake
apolipoprotein
j
precursor
platelet
factor
precursor
vitronectin
vn
demonstr
greatest
differ
express
level
signific
correl
liver
diseas
chosen
verifi
western
blot
use
western
blot
kit
forevergen
guangzhou
china
briefli
protein
lysat
separ
polyacrylamid
gel
electrophoresi
transfer
polyvinyliden
difluorid
pvdf
membran
subject
immunoblot
follow
antibodi
antiapolipoprotein
j
precursor
antibodi
dilut
abcam
cambridg
uk
antihemoglobin
dilut
santa
cruz
biotechnolog
inc
santa
cruz
ca
usa
anticrp
precursor
dilut
abcam
antiplatelet
factor
precursor
dilut
millipor
billerica
usa
antivn
dilut
abcam
overnight
wash
membran
incub
horseradish
peroxidaseconjug
secondari
antibodi
visual
use
enhanc
chemiluminesc
system
ecl
forevergen
guangzhou
china
tabl
ii
summar
clinic
characterist
patient
sampl
collect
itraq
identifi
differ
protein
differ
express
level
patient
hbvinduc
aclf
chb
respect
healthi
control
tabl
iii
protein
quantif
softwar
base
rel
content
isotop
report
group
use
mz
refer
show
signific
result
identifi
protein
lost
correspond
report
group
give
quantif
inform
specif
inform
reidentif
publish
futur
studi
protein
identifi
use
itraq
classifi
six
categori
base
protein
function
fig
five
protein
demonstr
greatest
differ
express
signific
correl
liver
diseas
verifi
use
western
blot
crp
precursor
hemoglobin
chain
variant
hb
swake
apolipoprotein
j
precursor
platelet
factor
precursor
vn
fig
tabl
iv
two
five
protein
classifi
accord
biolog
process
apolipoprotein
j
precursor
platelet
factor
precursor
proteom
research
potenti
use
effect
tool
studi
pathogenesi
establish
prognosi
determin
treatment
outcom
varieti
diseas
field
chb
proteom
wide
perform
presum
due
mechan
chb
complic
aim
studi
describ
chang
serum
protein
level
patient
chb
hbvinduc
aclf
respect
compar
healthi
control
use
itraq
western
blot
author
hypothes
approach
potenti
ultim
benefici
identif
protein
import
progress
hbv
infect
present
studi
uniqu
protein
identifi
patient
chb
hbvinduc
aclf
differ
express
compar
healthi
control
protein
belong
six
differ
categori
base
protein
function
two
five
protein
analyz
use
western
blot
classifi
accord
biolog
process
apolipoprotein
j
precursor
platelet
factor
precursor
biolog
function
remain
protein
hbv
infect
progress
analyz
yet
elucid
howev
number
theori
discuss
follow
section
crp
synthes
liver
acut
phase
protein
rapidli
identifi
plasma
case
infect
tissu
damag
crp
abl
activ
complement
enhanc
phagocytosi
facilit
remov
pathogen
microorgan
injur
necrot
apoptot
cell
therefor
crp
import
natur
immun
origin
crp
consid
nonspecif
biomark
inflamm
howev
follow
year
investig
demonstr
crp
particip
inflamm
atherosclerosi
directli
indic
prognost
factor
risk
factor
studi
reveal
level
precursor
crp
decreas
patient
chb
markedli
increas
patient
aclf
nearli
ident
chang
observ
hemoglobin
chain
variant
hb
swake
implic
orphan
diseas
although
liver
diseas
apolipoprotein
j
precursor
import
cell
age
tumorigenesi
apolipoprotein
j
lipid
transfer
inhibitor
protein
complement
corticosteroidbind
globulin
apolipoprotein
latter
five
marker
fibrosi
secret
blood
show
consist
chang
increas
stage
fibrosi
compar
marker
use
fibrotest
enhanc
liver
fibrosi
elf
hepascor
fibrospect
test
present
studi
level
apolipoprotein
j
precursor
decreas
progress
hbv
chb
aclf
therefor
studi
larger
number
sampl
requir
order
better
establish
role
apolipoprotein
j
precursor
potenti
biomark
hbv
progress
platelet
factor
chemotact
numer
cell
type
also
function
inhibitor
hematopoiesi
angiogenesi
tcell
function
may
use
biomark
establish
prognosi
sever
acut
respiratori
syndrom
chang
platelet
morpholog
accompani
increas
megathrombocyt
fraction
may
occur
chronic
liver
diseas
thrombocyt
activ
chronic
liver
diseas
liver
cirrhosi
platelet
sensit
stimuli
patient
liver
cirrhosi
demonstr
higher
healthi
control
indic
platelet
factor
activ
upregul
chronic
hepat
liver
cirrhosi
present
studi
level
platelet
factor
precursor
decreas
progress
hepat
b
liver
failur
result
suggest
studi
requir
investig
potenti
platelet
factor
precursor
biomark
progress
chb
vn
anoth
protein
commonli
featur
studi
liver
diseas
multifunct
plasma
glycoprotein
produc
hepatocyt
detect
plasma
extracellular
matrix
glycosyl
vn
modul
multimer
collagen
bind
liver
regener
alter
vn
glycosyl
modul
substrat
adhes
rat
hepat
stellat
cell
hsc
respons
matrix
restructur
immunoblot
data
identifi
increas
vn
level
cirrhot
liver
vn
immunoreact
shown
markedli
increas
cirrhot
liver
matrix
irrespect
appar
reduct
plasma
vn
vn
immunoreact
liver
may
consid
marker
fibrosi
particularli
chronicmatur
fibrosi
parallel
previou
observ
concern
enhanc
orcein
stain
cirrhot
septa
result
suggest
vn
may
import
progress
liver
diseas
andor
hepat
fibrosi
collagenbind
domain
vn
level
like
higher
patient
chronic
hepat
liver
cirrhosi
liver
cancer
control
present
studi
vn
level
decreas
progress
hepat
b
chb
hbvinduc
aclf
observ
decreas
vn
level
consist
two
studi
one
studi
demonstr
chronic
liver
diseas
concentr
plasma
vn
significantli
lower
healthi
control
associ
sever
liver
diseas
notabl
level
vn
liver
tissu
significantli
increas
patient
chronic
liver
diseas
compar
normal
control
result
suggest
vn
deposit
injur
tissu
repair
process
function
adhes
protein
studi
demonstr
lower
level
plasma
vn
chronic
liver
diseas
possibl
due
decreas
synthesi
deposit
injur
tissu
combin
two
group
author
also
reveal
decreas
level
plasma
vn
fibronectin
fn
increas
level
serum
laminin
lm
patient
chronic
liver
diseas
associ
hepat
dysfunct
chang
level
glycoprotein
involv
cell
attach
signific
develop
hepat
fibrosi
patient
chronic
liver
diseas
base
accumul
inform
vn
liver
fibrosi
appear
vn
requir
studi
present
studi
author
aim
describ
chang
serum
protein
level
patient
liver
dysfunct
induc
hepat
b
patient
sever
liver
damag
aclf
purpos
specif
identifi
one
protein
abl
serv
biomark
predict
pathogen
condit
prognost
purpos
similar
afp
hepatocellular
carcinoma
hcc
possibl
studi
obtain
seri
serum
sampl
individu
patient
progress
variou
stage
hepat
b
infect
sever
liver
damag
aclf
howev
use
itraq
western
blot
sever
candid
protein
identifi
name
apolipoprotein
j
precursor
platelet
factor
precursor
vn
warrant
studi
use
larger
number
sampl
